AMACR AND P53 IMMUNOHISTOCHEMISTRY FOR PREDICTING THE RISK OF NEOPLASTIC PROGRESSION IN DYSPLASTIC BARRETT’S ESOPHAGUS

(1) Erasmus University Medical Center



This item was part of the OESOPHAGEAL, GASTRIC AND DUODENAL DISORDERS III session at 20th United European Gastroenterology Week

This item can be cited as: Gut 2012; 61 (Suppl 3) A433